secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0000950170-23-007717
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences reports FY2022 net loss $140.2M, cash $259.3M; outlines bezuclastinib milestones for 2023
--------------------------------------------------------------------------------

- Net loss $39.6M Q4, $140.2M FY2022 vs $72.3M FY2021; R&D expenses $121.6M FY2022.
- Cash, equivalents and marketable securities $259.3M as of Dec 31, 2022; runway into 2025.
- APEX Part 2 initiation planned mid-2023; updated Phase 3 PEAK lead-in data expected 1H23.
- Initial SUMMIT Phase 2 data in nonadvanced systemic mastocytosis expected 2H23.
- Appointed Rachael Easton, M.D., Ph.D., VP Head of Clinical Development; Sylvia Adams to SAB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017023007717/0000950170-23-007717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017023007717/cogt-20230314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer